NEWSROOM

Medical Research

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Jun 3, 2025

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company’s Form 10 registration statement and SEC review process. BioStem believes it has favorably...

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

May 28, 2025

Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 - PRISM MediaWire - Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney...

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

May 22, 2025

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

May 12, 2025

NEW YORK, May 12, 2025 - PRISM MediaWire - In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its commitment to highlighting the critical importance of mental health and the ongoing efforts to improve mental well-being across the nation. Established in 1949 by Mental Health America, Mental Health Awareness Month serves to educate the public about mental illnesses, promote mental wellness, and reduce the stigma associated with mental health conditions. This year's...

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Welcomes Advocate Health as CLARITY Trial Site

May 5, 2025

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Apr 22, 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement Listen: PITTSBURGH, April 22, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% Listen: BROOMFIELD, Colo., April 21, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Apr 8, 2025

Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica Broomfield, CO, April 2, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan...

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025

The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Announces Reverse Stock Split

Mar 26, 2025

BROOMFIELD, Colo., March 26, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company’s stockholders...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025

IRVINE, Calif., March 18, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration: Register here An archived...

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Provides Shareholder Update

Mar 13, 2025

Broomfield, CO, March 13, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be viewed here: The Company intends on filing its 10K by the end of March and...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025

Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites Broomfield, CO, March 06, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion to Showcase Groundbreaking NOCISCAN™ Technology at the 2025 Spine Summit

Feb 20, 2025

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., February 20, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Feb 11, 2025

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 - PRISM...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Prices $29.1 Million Equity Offering

Feb 10, 2025

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships Irvine, Calif., Jan. 8, 2025 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Jan 7, 2025

Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003 New York, January 07, 2024 -PRISM MediaWire - PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24%...

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Dec 19, 2024

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, December 18, 2024 - PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Dec 9, 2024

January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13 - 16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors....

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Dec 6, 2024

IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

Dec 2, 2024

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis...

Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment

Dec 2, 2024

Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Nov 21, 2024

PITTSBURGH, November 21, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Nov 12, 2024

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third...